<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710056</url>
  </required_header>
  <id_info>
    <org_study_id>R4461-LEPR</org_study_id>
    <nct_id>NCT04710056</nct_id>
  </id_info>
  <brief_title>Expanded Access to REGN4461 for Patients With 1) Generalized Lipodystrophy, 2) Partial Lipodystrophy or 3) Monogenic Obesity Due to LEP or LEPR Loss of Function</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Provide Expanded Access to REGN4461 for Patients with 1) Generalized Lipodystrophy, 2)&#xD;
      Partial Lipodystrophy or 3) Monogenic Obesity due to LEP or LEPR Loss of Function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compassionate Use requests are only being considered in response to Individual Patient&#xD;
      Investigational New Drug (IND) applications. Availability will depend on location.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Generalized Lipodystrophy</condition>
  <condition>Partial Lipodystrophy</condition>
  <condition>Monogenic Obesity Due to LEP or LEPR Loss of Function</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN4461</intervention_name>
  </intervention>
  <overall_contact>
    <last_name>Requests for compassionate use must be initiated by a treating physician. Physicians should contact</last_name>
    <phone>844-734-6643</phone>
    <email>CompassionateUse_Requests@regeneron.com</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy, Congenital Generalized</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

